Exact Mass: 432.2359
Exact Mass Matches: 432.2359
Found 500 metabolites which its exact mass value is equals to given mass value 432.2359
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Buclizine
Buclizine is only found in individuals that have used or taken this drug. It is an antihistamine of the piperazine derivative family. [Wikipedia]Vomiting (emesis) is essentially a protective mechanism for removing irritant or otherwise harmful substances from the upper GI tract. Emesis or vomiting is controlled by the vomiting centre in the medulla region of the brain, an important part of which is the chemotrigger zone (CTZ). The vomiting centre possesses neurons which are rich in muscarinic cholinergic and histamine containing synapses. These types of neurons are especially involved in transmission from the vestibular apparatus to the vomiting centre. Motion sickness principally involves overstimulation of these pathways due to various sensory stimuli. Hence the action of buclizine which acts to block the histamine receptors in the vomiting centre and thus reduce activity along these pathways. Furthermore since buclizine possesses anti-cholinergic properties as well, the muscarinic receptors are similarly blocked. R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AE - Piperazine derivatives D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
2-piperidin-3-yloxy-8-propan-2-yl-N-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine
Glucosyl (2E,6E,10x)-10,11-dihydroxy-2,6-farnesadienoate
Glucosyl (2E,6E,10x)-10,11-dihydroxy-2,6-farnesadienoate is found in alcoholic beverages. Glucosyl (2E,6E,10x)-10,11-dihydroxy-2,6-farnesadienoate is present in Riesling wine. Present in Riesling wine. Glucosyl (2E,6E,10x)-10,11-dihydroxy-2,6-farnesadienoate is found in alcoholic beverages.
1-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phosphate
1-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phosphate is also known as PA(18:3(6Z,9Z,12Z)/0:0). 1-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phosphate is considered to be practically insoluble (in water) and acidic. 1-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phosphate is a glycerophosphate lipid molecule
1-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphate
1-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphate is also known as PA(18:3(9Z,12Z,15Z)/0:0). 1-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphate is considered to be practically insoluble (in water) and acidic. 1-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphate is a glycerophosphate lipid molecule
LysoPA(18:3(6Z,9Z,12Z)/0:0)
LysoPA(18:3(6Z,9Z,12Z)/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. LysoPA(18:3(6Z,9Z,12Z)/0:0), in particular, consists of one chain of gamma-linolenic acid at the C-1 position. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes.
LysoPA(18:3(9Z,12Z,15Z)/0:0)
LysoPA(18:3(9Z,12Z,15Z)/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. LysoPA(18:3(9Z,12Z,15Z)/0:0), in particular, consists of one chain of alpha-linolenic acid at the C-1 position. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes.
p-[(R)-3-[Bis-[(R)-beta-hydroxyphenethyl]amino]butyl]benzamide
Methylglutarylcarnitine
N-Methylphenylalanyl-prolyl-arginine
(1S,4S,5S,7R,10R)-10,11,14-trihydroxyguai-3-one 11-O-beta-D-glucopyranoside|(1S,4S,5S,7R,10R)-10,11,14-Trihydroxyguai-3-one 11-O-??-D-glucopyranoside|(1S,4S,5S,7R,10R)-10,11,14-trihydroxyguaian-3-one 11-O-beta-D-glucopyranoside
1beta,6beta,9alpha,11-tetrahydroxy-trans-eudesm-3-ene-6-O-beta-D-glucopyranoside
2,4,6-tri-O-acetyl-3-O-isobutyryl-1-O-2-methylbutyryl-chiro-inositol
(14R,16R,19S,20R)-(1-hydroxy-16,20-dimethyl-20-(24-methylpent-23-en-21-yl)- 14,15,16,17,18,19-hexahydro-6H-3,16-epoxybenzo[c]chromen-6-yl)(phenyl)methanone|benzophenone-congestiflorone
(1beta,4alphaH,5alpha,10betaH)-2beta,7alpha,8alpha-trihydroxy-10,11-epoxy-guaiane 2-O-beta-D-glucopyranoside|daucuside
2alpha,7,12-trihydroxykessane 2-O-beta-D-glucopyranoside
Ile Ser Val Asp
Buclizine
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AE - Piperazine derivatives D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Ala Glu Ile Thr
Ala Glu Leu Thr
Ala Glu Thr Ile
Ala Glu Thr Leu
Ala Phe Pro Val
Ala Phe Val Pro
Ala Ile Glu Thr
Ala Ile Met Val
Ala Ile Thr Glu
Ala Ile Val Met
Ala Lys Asn Thr
Ala Lys Gln Ser
Ala Lys Ser Gln
Ala Lys Thr Asn
Ala Leu Glu Thr
Ala Leu Met Val
Ala Leu Thr Glu
Ala Leu Val Met
Ala Met Ile Val
Ala Met Leu Val
Ala Met Val Ile
Ala Met Val Leu
Ala Asn Lys Thr
Ala Asn Thr Lys
Ala Pro Phe Val
Ala Pro Val Phe
Ala Gln Lys Ser
Ala Gln Ser Lys
Ala Ser Lys Gln
Ala Ser Gln Lys
Ala Thr Glu Ile
Ala Thr Glu Leu
Ala Thr Ile Glu
Ala Thr Lys Asn
Ala Thr Leu Glu
Ala Thr Asn Lys
Ala Val Phe Pro
Ala Val Ile Met
Ala Val Leu Met
Ala Val Met Ile
Ala Val Met Leu
Ala Val Pro Phe
Cys Ile Val Val
Cys Leu Val Val
Cys Val Ile Val
Cys Val Leu Val
Cys Val Val Ile
Cys Val Val Leu
Asp Ile Ser Val
Asp Ile Val Ser
Asp Leu Ser Val
Asp Leu Val Ser
Asp Ser Ile Val
Asp Ser Leu Val
Asp Ser Val Ile
Asp Ser Val Leu
Asp Thr Val Val
Asp Val Ile Ser
Asp Val Ser Ile
Asp Val Ser Leu
Asp Val Thr Val
Asp Val Val Thr
Glu Ala Ile Thr
Glu Ala Leu Thr
Glu Ala Thr Ile
Glu Ala Thr Leu
Glu Ile Ala Thr
Glu Ile Thr Ala
Glu Leu Ala Thr
Glu Leu Thr Ala
Glu Ser Val Val
Glu Thr Ala Ile
Glu Thr Ala Leu
Glu Thr Ile Ala
Glu Val Ser Val
Glu Val Val Ser
Phe Ala Pro Val
Phe Ala Val Pro
Phe Gly Ile Pro
Phe Gly Leu Pro
Phe Gly Pro Ile
Phe Gly Pro Leu
Phe Ile Gly Pro
Phe Ile Pro Gly
Phe Leu Gly Pro
Phe Leu Pro Gly
Phe Pro Ala Val
Phe Pro Gly Ile
Phe Pro Gly Leu
Phe Pro Ile Gly
Phe Pro Leu Gly
Phe Pro Val Ala
Phe Val Ala Pro
Phe Val Pro Ala
Gly Phe Ile Pro
Gly Phe Leu Pro
Gly Phe Pro Ile
Gly Phe Pro Leu
Gly Ile Phe Pro
Gly Ile Ile Met
Gly Ile Leu Met
Gly Ile Met Ile
Gly Ile Met Leu
Gly Ile Pro Phe
Gly Lys Gln Thr
Gly Lys Thr Gln
Gly Leu Phe Pro
Gly Leu Ile Met
Gly Leu Leu Met
Gly Leu Met Ile
Gly Leu Met Leu
Gly Leu Pro Phe
Gly Met Ile Ile
Gly Met Ile Leu
Gly Met Leu Ile
Gly Met Leu Leu
Gly Pro Phe Ile
Gly Pro Phe Leu
Gly Pro Ile Phe
Gly Pro Leu Phe
Gly Gln Lys Thr
Gly Gln Thr Lys
Gly Thr Lys Gln
Gly Thr Gln Lys
Ile Ala Glu Thr
Ile Ala Met Val
Ile Ala Thr Glu
Ile Ala Val Met
Ile Cys Val Val
Ile Asp Ser Val
Ile Asp Val Ser
Ile Glu Ala Thr
Ile Glu Thr Ala
Ile Phe Gly Pro
Ile Phe Pro Gly
Ile Gly Phe Pro
Ile Gly Ile Met
Ile Gly Leu Met
Ile Gly Met Ile
Ile Gly Met Leu
Ile Gly Pro Phe
Ile Ile Gly Met
Ile Ile Met Gly
Ile Leu Gly Met
Ile Leu Met Gly
Ile Met Ala Val
Ile Met Gly Ile
Ile Met Gly Leu
Ile Met Ile Gly
Ile Met Leu Gly
Ile Met Val Ala
Ile Pro Phe Gly
Ile Pro Gly Phe
Ile Ser Asp Val
Ile Thr Ala Glu
Ile Thr Glu Ala
Ile Val Ala Met
Ile Val Cys Val
Ile Val Asp Ser
Ile Val Met Ala
Ile Val Ser Asp
Ile Val Val Cys
Lys Ala Asn Thr
Lys Ala Gln Ser
Lys Ala Ser Gln
Lys Ala Thr Asn
Lys Gly Gln Thr
Lys Gly Thr Gln
Lys Asn Ala Thr
Lys Asn Thr Ala
Lys Gln Ala Ser
Lys Gln Gly Thr
Lys Gln Ser Ala
Lys Gln Thr Gly
Lys Ser Ala Gln
Lys Ser Gln Ala
Lys Thr Ala Asn
Lys Thr Gly Gln
Lys Thr Asn Ala
Lys Thr Gln Gly
Leu Ala Glu Thr
Leu Ala Met Val
Leu Ala Thr Glu
Leu Ala Val Met
Leu Cys Val Val
Leu Asp Ser Val
Leu Asp Val Ser
Leu Glu Ala Thr
Leu Glu Thr Ala
Leu Phe Gly Pro
Leu Phe Pro Gly
Leu Gly Phe Pro
Leu Gly Ile Met
Leu Gly Leu Met
Leu Gly Met Ile
Leu Gly Met Leu
Leu Gly Pro Phe
Leu Ile Gly Met
Leu Ile Met Gly
Leu Leu Gly Met
Leu Leu Met Gly
Leu Met Ala Val
Leu Met Gly Ile
Leu Met Gly Leu
Leu Met Ile Gly
Leu Met Leu Gly
Leu Met Val Ala
Leu Pro Phe Gly
Leu Pro Gly Phe
Leu Ser Asp Val
Leu Ser Val Asp
Leu Thr Ala Glu
Leu Thr Glu Ala
Leu Val Ala Met
Leu Val Cys Val
Leu Val Asp Ser
Leu Val Met Ala
Leu Val Ser Asp
Leu Val Val Cys
Met Ala Ile Val
Met Ala Leu Val
Met Ala Val Ile
Met Ala Val Leu
Met Gly Ile Ile
Met Gly Ile Leu
Met Gly Leu Ile
Met Gly Leu Leu
Met Ile Ala Val
Met Ile Gly Ile
Met Ile Gly Leu
Met Ile Ile Gly
Met Ile Leu Gly
Met Ile Val Ala
Met Leu Ala Val
Met Leu Gly Ile
Met Leu Gly Leu
Met Leu Ile Gly
Met Leu Leu Gly
Met Leu Val Ala
Met Val Ala Ile
Met Val Ala Leu
Met Val Ile Ala
Met Val Leu Ala
Asn Ala Lys Thr
Asn Ala Thr Lys
Asn Lys Ala Thr
Asn Lys Thr Ala
Asn Thr Ala Lys
Asn Thr Lys Ala
Pro Ala Phe Val
Pro Ala Val Phe
Pro Phe Ala Val
Pro Phe Gly Ile
Pro Phe Gly Leu
Pro Phe Ile Gly
Pro Phe Leu Gly
Pro Phe Val Ala
Pro Gly Phe Ile
Pro Gly Phe Leu
Pro Gly Ile Phe
Pro Gly Leu Phe
Pro Ile Phe Gly
Pro Ile Gly Phe
Pro Leu Phe Gly
Pro Leu Gly Phe
Pro Val Ala Phe
Pro Val Phe Ala
Gln Ala Lys Ser
Gln Ala Ser Lys
Gln Gly Lys Thr
Gln Gly Thr Lys
Gln Lys Ala Ser
Gln Lys Gly Thr
Gln Lys Ser Ala
Gln Lys Thr Gly
Gln Ser Ala Lys
Gln Ser Lys Ala
Gln Thr Gly Lys
Gln Thr Lys Gly
Ser Ala Lys Gln
Ser Ala Gln Lys
Ser Asp Ile Val
Ser Asp Leu Val
Ser Asp Val Ile
Ser Asp Val Leu
Ser Glu Val Val
Ser Ile Asp Val
Ser Ile Val Asp
Ser Lys Ala Gln
Ser Lys Gln Ala
Ser Leu Val Asp
Ser Gln Ala Lys
Ser Gln Lys Ala
Ser Val Asp Ile
Ser Val Asp Leu
Ser Val Glu Val
Ser Val Ile Asp
Ser Val Leu Asp
Ser Val Val Glu
Thr Ala Glu Ile
Thr Ala Glu Leu
Thr Ala Ile Glu
Thr Ala Lys Asn
Thr Ala Leu Glu
Thr Ala Asn Lys
Thr Glu Leu Ala
Thr Gly Lys Gln
Thr Gly Gln Lys
Thr Lys Ala Asn
Thr Lys Gly Gln
Thr Lys Asn Ala
Thr Lys Gln Gly
Thr Leu Ala Glu
Thr Leu Glu Ala
Thr Asn Ala Lys
Thr Asn Lys Ala
Thr Gln Gly Lys
Thr Gln Lys Gly
Thr Val Asp Val
Thr Val Val Asp
Val Ala Phe Pro
Val Ala Ile Met
Val Ala Leu Met
Val Ala Met Ile
Val Ala Met Leu
Val Ala Pro Phe
Val Cys Ile Val
Val Cys Leu Val
Val Cys Val Ile
Val Cys Val Leu
Val Asp Ser Ile
Val Asp Ser Leu
Val Asp Thr Val
Val Asp Val Thr
Val Glu Ser Val
Val Glu Val Ser
Val Phe Ala Pro
Val Phe Pro Ala
Val Ile Ala Met
Val Ile Cys Val
Val Ile Asp Ser
Val Ile Met Ala
Val Ile Ser Asp
Val Ile Val Cys
Val Leu Ala Met
Val Leu Cys Val
Val Leu Asp Ser
Val Leu Met Ala
Val Leu Ser Asp
Val Leu Val Cys
Val Met Ala Ile
Val Met Ala Leu
Val Met Ile Ala
Val Met Leu Ala
Val Pro Ala Phe
Val Pro Phe Ala
Val Ser Asp Ile
Val Ser Asp Leu
Val Ser Glu Val
Val Ser Ile Asp
Val Ser Leu Asp
Val Ser Val Glu
Val Thr Asp Val
Val Thr Val Asp
Val Val Cys Ile
Val Val Cys Leu
Val Val Asp Thr
Val Val Glu Ser
Val Val Ile Cys
Val Val Leu Cys
Val Val Ser Glu
Val Val Thr Asp
Glucosyl (2E,6E,10x)-10,11-dihydroxy-2,6-farnesadienoate
1-N-Boc-4-(3-Cbz-amino-3-methoxycarbonylallyl)piperidine
Bms-911543
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C125450 - JAK2 Inhibitor
(R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol
PF-04995274 is a potent, high-affinity, orally active and partial serotonin 4 receptor (5-HT4R) agonist. PF-04995274 has an EC50 range of 0.26-0.47 nM for human 5-HT4A/4B/4D/4E (Ki range of 0.15-0.46 nM), and has an EC50 range of 0.59-0.65 nM for rat 5-HT4S/4L/4E (Ki of 0.30 nM for rat 5-HT4S). PF-04995274 is brain penetrant and can be used for cognitive disorders associated with Alzheimer's disease[1][2][3].
Platensimide A
A polycyclic cage compound that is a carboxamide obtained by the formal condensation of the amino group of 4-(acetylamino)-2-aminobutanoic acid with the carboxy group of the oxatetracyclic cage component. It is isolated from Streptomyces platensis.
1,4,8,11-tetraazacyclotetradecane-N,N,N,N-tetraacetic acid
1,1-(1,3-Phenylenebis(propane-2,2-diyl))bis(3-(pyridin-3-yl)urea)
N-Methylphenylalanyl-prolyl-arginine
(3R,4S,6R)-N-[(2-methoxyphenyl)methyl]-6-[(4-pyridin-2-yltriazol-1-yl)methyl]-1-azabicyclo[2.2.2]octane-3-carboxamide
(R)-4-Benzyloxy-2-methylbutyl tert-butyldiphenylsilyl ether
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
[(8S,9S,10R)-9-[4-(2-fluorophenyl)phenyl]-6-(5-pyrimidinylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8R,9R,10S)-9-[4-(2-fluorophenyl)phenyl]-6-(5-pyrimidinylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9S,10S)-9-[4-(2-fluorophenyl)phenyl]-6-(5-pyrimidinylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
[(8S,9R,10R)-9-[4-(2-fluorophenyl)phenyl]-6-(5-pyrimidinylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8R,9R,10R)-9-[4-(2-fluorophenyl)phenyl]-6-(5-pyrimidinylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9R,10S)-9-[4-(2-fluorophenyl)phenyl]-6-(5-pyrimidinylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8R,9S,10R)-9-[4-(2-fluorophenyl)phenyl]-6-(5-pyrimidinylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8R,9S,10S)-9-[4-(2-fluorophenyl)phenyl]-6-(5-pyrimidinylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
1-Linoleoylglycerone 3-phosphate
A 1-acylglycerone 3-phosphate in which the acyl group is specified as linoleoyl.
2-Hydroxy-3-(phosphonooxy)propyl (9Z,12Z,15Z)-9,12,15-octadecatrienoate
1-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphate
1-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phosphate
Asp-Leu-Val-Ser
A tetrapeptide composed of L-aspartic acid, L-leucine, L-valine and L-serine units joined in sequence.
1-Oleoylglycerone 3-phosphate(2-)
A 1-acylglycerone 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-oleoylglycerone 3-phosphate; major species at pH 7.3.
1-(gamma-linolenoyl)-sn-glycero-3-phosphate
A 1-acyl-sn-glycerol 3-phosphate in which the 1-acyl substituent is specified as gamma-linolenoyl (6Z,9Z,12Z-octadecatrienoyl).
1-linolenoyl-sn-glycero-3-phosphate
A 1-acyl-sn-glycerol 3-phosphate in which the 1-acyl substituent is specified as linolenoyl (9Z,12Z,15Z-octadecatrienoyl).
1-Linoleoyl-sn-glycero-3-phosphate(2-)
A 1-acyl-sn-glycerol 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-linoleoyl-sn-glycero-3-phosphate.
(2s,3r,4s,5s,6r)-2-{[(1r,2r,4s)-2,4-dihydroxy-2-[(1e,3e)-5-hydroxy-3-methylpenta-1,3-dien-1-yl]-1,3,3-trimethylcyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
2-{[5-hydroxy-4a-(hydroxymethyl)-2-(2-hydroxypropan-2-yl)-8-methyl-2,3,4,5,6,8a-hexahydro-1h-naphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r,3r,4s,5s,6r)-2-{[(1s,2r,4as,5s,8ar)-5-hydroxy-4a-(hydroxymethyl)-2-(2-hydroxypropan-2-yl)-8-methylidene-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
3-ethylidene-2-{9h-pyrido[3,4-b]indol-1-ylmethyl}-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
(3r,4ar,5s,6s,8ar)-6-hydroxy-3-(2-hydroxypropan-2-yl)-5,8a-dimethyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-hexahydro-1h-naphthalen-2-one
2-{[5-hydroxy-4a-(hydroxymethyl)-2-(2-hydroxypropan-2-yl)-8-methylidene-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r,3r,4s,5s,6r)-2-{[(1r,2r,3r,5r,6r,8s,12s)-8,12-dihydroxy-1,5,9,9-tetramethyl-10-oxatricyclo[6.2.2.0²,⁶]dodecan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r,4s,5s,6r)-2-{[(1r,2r,4s)-2,4-dihydroxy-2-(5-hydroxy-3-methylpenta-1,3-dien-1-yl)-1,3,3-trimethylcyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
3β-angeloyloxy-10β-hydroxy-6β-methoxy-eremophila-7(11),8(9)-dien-8,12-olide
{"Ingredient_id": "HBIN008180","Ingredient_name": "3\u03b2-angeloyloxy-10\u03b2-hydroxy-6\u03b2-methoxy-eremophila-7(11),8(9)-dien-8,12-olide","Alias": "NA","Ingredient_formula": "C26H37ClO3","Ingredient_Smile": "COC(=O)CCCC=CCC1C(CCC1Cl)C2=CC=C(C=C2)C(C3CCCCC3)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1227","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
3-eudesmene-1,6,11,14-tetrol; (1α,5β,6β,10α)-form,6-o-beta-d-glucopyranoside
{"Ingredient_id": "HBIN008540","Ingredient_name": "3-eudesmene-1,6,11,14-tetrol; (1\u03b1,5\u03b2,6\u03b2,10\u03b1)-form,6-o-beta-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C21H36O9","Ingredient_Smile": "NA","Ingredient_weight": "432.51","OB_score": "NA","CAS_id": "202278-90-8","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8132","PubChem_id": "NA","DrugBank_id": "NA"}
4,14-epoxy-1,6,11-eudesmanetriol; (1α,4α,5β,6β,10α)-form,6-o-beta-d-glucopyranoside
{"Ingredient_id": "HBIN009819","Ingredient_name": "4,14-epoxy-1,6,11-eudesmanetriol; (1\u03b1,4\u03b1,5\u03b2,6\u03b2,10\u03b1)-form,6-o-beta-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C21H36O9","Ingredient_Smile": "NA","Ingredient_weight": "432.51","OB_score": "NA","CAS_id": "202278-88-4","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7937","PubChem_id": "NA","DrugBank_id": "NA"}
4(15)-eudesmene-1,6,11,14-tetrol; (1α,5β,6β,10α)-form,6-o-beta-d-glucopyranoside
{"Ingredient_id": "HBIN009831","Ingredient_name": "4(15)-eudesmene-1,6,11,14-tetrol; (1\u03b1,5\u03b2,6\u03b2,10\u03b1)-form,6-o-beta-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C21H36O9","Ingredient_Smile": "NA","Ingredient_weight": "432.51","OB_score": "NA","CAS_id": "202278-89-5","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7975","PubChem_id": "NA","DrugBank_id": "NA"}